IMABI-Mab

Nasdaq i-mabbiopharma.com


$ 1.75 $ 0.00 (0.29 %)    

Monday, 20-May-2024 15:59:54 EDT
QQQ $ 454.82 $ 3.15 (0.7 %)
DIA $ 398.57 $ -1.85 (-0.46 %)
SPY $ 530.36 $ 0.61 (0.12 %)
TLT $ 91.26 $ -0.27 (-0.3 %)
GLD $ 225.37 $ 0.90 (0.4 %)
$ 1.755
$ 1.77
$ 0.00 x 0
$ 0.00 x 0
$ 1.75 - $ 1.77
$ 1.16 - $ 3.38
147,096
na
14.16M
$ 0.81
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 needham-reiterates-buy-on-i-mab-maintains-6-price-target

Needham analyst Gil Blum reiterates I-MAB (NASDAQ:IMAB) with a Buy and maintains $6 price target.

 nvidia-to-rally-around-20-here-are-10-top-analyst-forecasts-for-monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

 piper-sandler-maintains-overweight-on-i-mab-lowers-price-target-to-10

Piper Sandler analyst Joseph Catanzaro maintains I-MAB (NASDAQ:IMAB) with a Overweight and lowers the price target from $15 ...

 hc-wainwright--co-reiterates-buy-on-i-mab-lowers-price-target-to-8

HC Wainwright & Co. analyst Andrew Fein reiterates I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $18 t...

 needham-maintains-buy-on-i-mab-lowers-price-target-to-6

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $8 to $6.

 i-mab-fy23-eps-076-vs-163-yoy-revenue-39m-vs-321m-yoy-fy23-epads-176-vs-375-yoy

Non-GAAP Net LossNon-GAAP adjusted net loss, which excludes share-based compensation expenses and impairment of goodwill, for t...

 needham-maintains-buy-on-i-mab-lowers-price-target-to-8

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $23 to $8.

 i-mab-inks-deal-to-divest-its-assets-and-business-operations-in-china

The Company will transfer 100% of the outstanding equity interest in I-Mab Biopharma Co., Ltd., a wholly owned subsidiary of th...

 t-investment-reports-989-stake-in-i-mab

-SEC Filing

 i-mab-abl-bio-announce-latest-updates-of-pd-l1-and-4-1bb-bispecific-antibody-tj-l14babl503

Among 14 efficacy-evaluable patients in the ongoing Phase 1 study, one achieved a complete response, one had partial response a...

 expert-ratings-for-i-mab
Expert Ratings for I-MAB
09/25/2023 20:00:18

 needham-maintains-buy-on-i-mab-lowers-price-target-to-23

Needham analyst Gil Blum maintains I-MAB (NASDAQ:IMAB) with a Buy and lowers the price target from $24 to $23.

Core News & Articles

- Reuters

Core News & Articles

- Reuters

Core News & Articles

- Reuters

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION